Case Report {#sec1_1}
===========

An 80-year-old Caucasian male presented for evaluation and management of multiple pruritic, painful nodules on his right lower extremity. These lesions had been enlarging over a 3-month duration. Biopsies from the right lateral and medial lower leg revealed neuroendocrine tumors consistent with poorly differentiated Merkel cell carcinoma (MCC).

Physical examination revealed 3 lesions on the right ankle. These shiny erythematous nodules displayed some focal hyperpigmentation and ranged in size from 1 to 3 cm in diameter. On palpation, all lesions were warm and slightly tender. No inguinal adenopathy was identified, and 1+ pitting edema of the involved right lower extremity was present. His past medical history was noncontributory.

Histologic review of the biopsy revealed a tumor extensively involving the entire thickness of the dermis that was distributed in sheets, clusters, and single cells. Tumor cells showed features including scant cytoplasm, dusty chromatin, and nuclear molding, and demonstrated dot-like cytokeratin (CK) 20 positivity (fig. [1](#F1){ref-type="fig"}). Additionally, the tumor cells were positive for synaptophysin, chromogranin, neuron-specific enolase (NSE), and epithelial membrane antigen (EMA), and negative for CD45, PSA, CK7, and thyroid-transcription factor 1 (TTF-1). Taking histologic and immunohistochemical findings into account, we confirmed a diagnosis of multiple primary cutaneous MCC. Given the rarity of this entity and anatomic location of lesions on the lower extremities, a differential diagnosis of metastatic neuroendocrine carcinoma from an alternate primary site was still considered (table [1](#T1){ref-type="table"}) \[[@B1]\]. A complete clinical workup including CT imaging of the chest, abdomen, and pelvis revealed no evidence of disease elsewhere, further supporting our diagnosis of an unusual case of multiple cutaneous MCC involving the lower extremity.

Due to the rapid progression and location of these lesions, surgical management with excision and reconstruction would be an extensive endeavor. CT angiography studies in our patient demonstrated poor runoff below the knee, which indicated insufficient vascular support necessary for free flap reconstruction. When presented with amputation as the only surgical option, our patient instead elected radiation therapy for local control. Prior to the initiation of radiotherapy, he developed several small satellite lesions proximally on the same leg (fig. [2](#F2){ref-type="fig"}). A radiation plan was created to treat the entire lower leg with 46 Gy in 23 fractions using intensity modulated photons, sparing a small strip along the lateral edge to decrease the risk of lymphedema. The gross residual disease was boosted with electron fields for a total of 54 Gy in 27 fractions. The patient had a rewarding response to treatment with clearing of the small satellite lesions and marked decrease of the large lesions during treatment and final resolution at the end of treatment (fig. [3](#F3){ref-type="fig"}). The patient will continue to be closely monitored to confirm complete remission.

Discussion {#sec1_2}
==========

MCC is a rare, aggressive neuroendocrine tumor of the skin that most commonly presents in white males in their 7th or 8th decade of life \[[@B2]\]. It is a highly metastatic disease, with a 5-year disease-specific survival rate of 64% \[[@B3]\]. As survival has been shown to decrease rapidly with advancing disease stage, early recognition by clinicians may improve survival \[[@B3],[@B4]\]. The most common site of presentation is on sun-exposed skin, usually the head and neck region, with 29-53% located here according to several studies \[[@B2],[@B3],[@B4]\]. Approximately 35-38% of cases involve the extremities \[[@B2],[@B3]\], further broken down to 21% on the upper extremities and only 14-24% on the lower extremities \[[@B4],[@B5]\]. Classically known to be a tumor of the head and neck region, primary cutaneous MCC has rarely been reported on the lower leg, with a review of the literature revealing only 5 case reports \[[@B5],[@B6],[@B7],[@B8],[@B9]\].

MCC often has a nonspecific clinical appearance and can present as persistent, asymptomatic pink to red solitary or grouped dome-shaped nodule(s), smaller than 2 cm, that grow rapidly over several months \[[@B2],[@B4]\]. Interestingly, Heath et al. \[[@B4]\] found that the majority of initial clinical impressions at the time of biopsy were benign, with cyst or acneiform lesion being the most common presumptive diagnosis of later confirmed MCC. To assist clinicians in the recognition of lesions concerning for MCC, the authors described a mnemonic entitled 'AEIOU' (A for asymptomatic/lack of tenderness, E for expanding rapidly, I for immune suppression, O for older than 50 years, and U for ultraviolet-exposed site on a person with fair skin) \[[@B4]\].

Because of its often nonspecific clinical presentation, histologic confirmation is necessary to help diagnose and differentiate MCC from a metastasis emanating from another neuroendocrine carcinoma, such as small-cell lung cancer (SCLC), lymphoma, or melanoma. Histologically, MCC presents as uniform, small blue cells filling the dermis, with scant cytoplasm, dusty chromatin, and nuclear molding. The cells arrange in sheets and nests, spreading to the reticular dermis and subcutis, with occasional epidermal involvement \[[@B2]\]. MCC possesses both neuroendocrine and epithelial features, expressing neuroendocrine markers such as chromogranin, synaptophysin, NSE, and neurofilament, as well as epithelial markers like AE1/AE3, EMA, CAM 5.2, and CK20 \[[@B2],[@B5]\]. The morphologic similarity between these cancers has made immunohistochemical staining invaluable, with dot-like, paranuclear expression of CK20 being a key differentiating marker for MCC \[[@B2]\]. In contrast, MCC is negative for CK7 and TTF-1, leukocyte common antigen/CD45, and S100, differentiating it from SCLC, lymphoma, and melanoma, respectively \[[@B2]\].

More recently, Merkel cell polyomavirus (MCPyV) has been found to be present in approximately 80% of all MCC \[[@B10],[@B11]\]. This viral infection appears to play a role in the pathogenesis of MCC, as it is seen more frequently than expected among immunosuppressed transplant and AIDS patients, and was found to be integrated into the genome before clonal expansion of the tumor cells \[[@B10]\]. Two MCPyV-specific stains, Ab3 and CM2B4, have been developed for use in diagnosis \[[@B11],[@B12]\].

Despite the aid that such immunohistochemical stains provide in the diagnosis of MCC, the possibility of a metastatic neuroendocrine carcinoma from an alternate primary site should be entertained. A complete clinical workup including CT scans of the chest, abdomen, and pelvis or PET scan can be performed to rule out this possibility.

Due to the low incidence of MCC, there are no clear treatment guidelines validated by prospective randomized controlled clinical trials. The historical standard of care has thus far been surgical excision with 2-3 cm margins and sentinel lymph node biopsy \[[@B3],[@B13]\]. There is strong evidence for the addition of adjuvant radiation, but not for adjuvant chemotherapy \[[@B14]\]. Systemic therapies such as etoposide, vincristine, anthracyclines, antimetabolites, and platinum derivatives have all been used to treat advanced disease with high remission rates; however, multiple studies have shown no significant increase in survival time and even decreased survival, with a high degree of toxicity, given the elderly treatment population \[[@B3],[@B13],[@B14]\]. For this reason, adjuvant chemotherapy is generally not recommended. While adjuvant radiation has been shown to have clear added benefit when combined with surgical excision, more recent studies have found that radiation therapy as an exclusive treatment for unresectable disease has a control rate similar to that of conventional treatment (surgical excision plus adjuvant radiation) \[[@B13],[@B14],[@B15]\]. Doses of 50 Gy or more for subclinical disease and 55 Gy or more for gross disease are recommended to obtain field disease control \[[@B13],[@B15]\].

In our patient, advanced age and anatomic location precluded the possibility of wide-local excision, leaving amputation as the only surgical option. He was offered radiation therapy alone and received a total of 54 Gy in 27 fractions to the bulky disease area, with 46 Gy in 23 fractions to the remaining leg. Our patient obtained an excellent clinical response, lasting 2 months at present despite extensive disease. This case highlights definitive radiotherapy as an effective treatment option for inoperable MCC due to advanced age, comorbidities, and/or cosmetic or functional deficits.
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![Histologic features of the lesion. **a** Hematoxylin-eosin: sheets and clusters of uniform, small, round blue cells filling the dermis, with scant cytoplasm, dusty chromatin, and nuclear molding (×9). Inset shows a higher-power view (×20). **b** Characteristic paranuclear, dot-like pattern of CK20 staining (×30). Synaptophysin, chromogranin, and NSE were expressed as well.](cde-0007-0316-g01){#F1}

![Clinical features of the lesions of the right anterior lower leg prior to treatment.](cde-0007-0316-g02){#F2}

![Clinical features of the right posterior lower leg prior to treatment (**a**), 2 weeks into radiation therapy (**b**), and 5 weeks after treatment (**c**).](cde-0007-0316-g03){#F3}

###### 

Immunohistochemical staining profile of MCC and its differentiation from neuroendocrine tumors and other entities in the differential diagnosis \[[@B2]\]

  CK20                                            TTF-1   CK7   NSE                                       Chromo-granin   Synapto-physin   S100   LCA/CD45   AE1/AE3   
  ----------------------------------------------- ------- ----- ----------------------------------------- --------------- ---------------- ------ ---------- --------- -----
  MCC                                             \+      −     − (+[^\*^](#T1F1){ref-type="table-fn"})   \+              \+               \+     −          −         \+
  SCLC                                            −       \+    \+                                        \+              \+               \+     −          −         \+
  Lymphoma                                        −       −     −                                         −               −                −      −          \+        −
  Melanoma                                        −       −     −                                         \+              −                −      \+         −         −
  Ewing sarcoma/primitive neuroectodermal tumor   −       −     −                                         \+              −                +/−    +/−        −         +/−

LCA = Leukocyte common antigen.

Rare cases of CK7-positive MCC have been reported \[[@B1]\].
